» Articles » PMID: 22013219

Description of Antiviral Treatment Among Adults Hospitalized with Influenza Before and During the 2009 Pandemic: United States, 2005-2009

Abstract

Background: The 2009 influenza pandemic led to guidelines emphasizing antiviral treatment for all persons hospitalized with influenza, including pregnant women. We compared antiviral use among adults hospitalized with influenza before and during the pandemic.

Methods: The Emerging Infections Program conducts active population-based surveillance for persons hospitalized with community-acquired, laboratory-confirmed influenza in 10 states. We analyzed data collected via medical record review of patients aged ≥18 years admitted during prepandemic (1 October 2005 through 14 April 2009) and pandemic (15 April 2009 through 31 December 2009) time frames.

Results: Of 5943 adults hospitalized with influenza in prepandemic seasons, 3235 (54%) received antiviral treatment, compared with 4055 (82%) of 4966 during the pandemic. Forty-one (22%) of 187 pregnant women received antiviral treatment in prepandemic seasons, compared with 369 (86%) of 430 during the pandemic. Pregnancy was a negative predictor of antiviral treatment before the pandemic (adjusted odds ratio [aOR], 0.24; 95% confidence interval [CI], .16-.35) but was independently associated with treatment during the pandemic (aOR, 1.97; 95% CI, 1.32-2.96). Antiviral treatment among adults hospitalized >2 days after illness onset increased from 43% before the pandemic to 79% during the pandemic (P < .001).

Conclusions: Antiviral treatment of hospitalized adults increased during the pandemic, especially among pregnant women. This suggests that many clinicians followed published guidance to treat hospitalized adults with antiviral agents. However, compliance with antiviral recommendations could be improved.

Citing Articles

Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.

Adlhoch C, Delgado-Sanz C, Carnahan A, Larrauri A, Popovici O, Bossuyt N Euro Surveill. 2023; 28(4).

PMID: 36700868 PMC: 9881178. DOI: 10.2807/1560-7917.ES.2023.28.4.2200340.


Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015-2019.

Tenforde M, Cummings C, OHalloran A, Rothrock G, Kirley P, Alden N Open Forum Infect Dis. 2023; 10(1):ofac681.

PMID: 36686630 PMC: 9846184. DOI: 10.1093/ofid/ofac681.


Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.

Deng R, She G, Maia M, Lim J, Peck M, McBride J J Clin Pharmacol. 2020; 60(11):1509-1518.

PMID: 32621543 PMC: 7586956. DOI: 10.1002/jcph.1652.


Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

McBride J, Lim J, Burgess T, Deng R, Derby M, Maia M Antimicrob Agents Chemother. 2017; 61(11).

PMID: 28807912 PMC: 5655070. DOI: 10.1128/AAC.01154-17.


Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia.

Oboho I, Bramley A, Finelli L, Fry A, Ampofo K, Arnold S Open Forum Infect Dis. 2017; 4(1):ofw254.

PMID: 28480248 PMC: 5413989. DOI: 10.1093/ofid/ofw254.